| EDUCATIONAL FORUM |
|
| Year : 2016 | Volume
: 48
| Issue : 5 | Page : 481-486 |
Preclinical screening methods in cancer
Sachin Kumar1, Sakshi Bajaj2, Ramesh Babu Bodla3
1 Department of Pharmacology, DIPSAR, New Delhi, India
2 Department of Herbal Drug Technology, DIPSAR, New Delhi, India
3 Department of Pharmaceutical Chemistry, DIPSAR, New Delhi, India
Correspondence Address:
Dr. Ramesh Babu Bodla
Department of Pharmaceutical Chemistry, DIPSAR, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.190716
Cancer, a group of diseases of unregulated cell proliferation, is a leading cause of death worldwide. More than 80% of compounds which have shown promising effects in preclinical studies could not get through Phase II of clinical trials. Such high attrition rate is due to improper or selective use of preclinical modalities in anticancer drug screening. The various preclinical screening methods available such as in vitro human cancer cell lines, in vivo tumor xenograft model, or genetically engineered mouse model have their respective pros and cons. Scrupulous use of these preclinical screening methods vis-ΰ-vis efficacy of potential anticancer compound with diverse mechanism of action can help in bringing down the rate of failure of anticancer compound at clinical phase. This article provides an insight into the various preclinical methods used in anticancer studies along with their advantages and disadvantages.
[FULL TEXT] [PDF]*
|
